| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
5,780,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3302 - $0.3302 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Phio Pharmaceuticals is developing therapeutics that use its INTASYL™ technology to target both tumor and immune cells by regulating genes to strengthen a patient's immune system while weakening tumor defense mechanisms. Co.'s INTASYL-based therapeutics are used to: strengthen immune cells, for example those administered as part of adoptive cell therapy (ACT), and directly modify cells in the tumor microenvironment to weaken a tumor's defense. Co.'s lead product candidate being developed by Co. in ACT is PH-762. Co.'s second product candidate in development for use in ACT is PH-894. Co.'s INTASYL compound PH-804 is also being developed for use in ACT.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
10,200 |
12,700 |
17,200 |
| Total Buy Value |
$0 |
$22,461 |
$27,011 |
$30,776 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
5 |
6 |
9 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-08-21 |
2025-05-20 |
2024-11-19 |
2023-11-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bitterman Robert J |
Chairman, Pres. & CEO |
• • – |
2025-11-18 |
4 |
B |
$1.27 |
$6,350 |
D/D |
5,000 |
276,421 |
2.81 |
- |
|
| Bitterman Robert J |
Chairman, Pres. & CEO |
• • – |
2025-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
271,421 |
|
- |
|
| Bitterman Robert J |
Chairman, Pres. & CEO |
• • – |
2025-09-11 |
4 |
D |
$2.32 |
$9,538 |
D/D |
(4,111) |
21,421 |
|
- |
|
| Ferrara Robert L |
Director |
– • – |
2025-09-11 |
4/A |
A |
$0.00 |
$0 |
D/D |
23,100 |
38,766 |
|
- |
|
| Freeman Jonathan E |
Director |
– • – |
2025-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
14,700 |
16,055 |
|
- |
|
| Ferrara Robert L |
Director |
– • – |
2025-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
23,000 |
38,666 |
|
- |
|
| Carson Lisa Cabott |
VP, Finance and Administration |
• – – |
2025-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
47,000 |
47,000 |
|
- |
|
| Deming David H |
Director |
– • – |
2025-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
14,000 |
|
- |
|
| Lockshin Curtis |
Director |
– • – |
2025-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
16,200 |
18,555 |
|
- |
|
| Bradford Patricia A |
Director |
– • – |
2025-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
18,800 |
27,151 |
|
- |
|
| Ferrara Robert L |
Director |
– • – |
2025-06-10 |
4 |
B |
$2.42 |
$6,050 |
D/D |
2,500 |
15,666 |
2.39 |
- |
|
| Bitterman Robert J |
Chairman, Pres & CEO |
• • – |
2025-06-10 |
4 |
B |
$2.42 |
$4,840 |
D/D |
2,000 |
27,149 |
2.73 |
- |
|
| Bitterman Robert J |
Chairman, Pres & CEO |
• • – |
2025-06-09 |
4 |
B |
$2.75 |
$4,125 |
D/D |
1,500 |
25,149 |
2.73 |
- |
|
| Bitterman Robert J |
Chairman, Pres & CEO |
• • – |
2025-05-22 |
4 |
B |
$1.78 |
$2,136 |
D/D |
1,200 |
23,649 |
2.73 |
- |
|
| Bitterman Robert J |
Chairman, Pres & CEO |
• • – |
2025-05-21 |
4 |
B |
$1.77 |
$5,310 |
D/D |
3,000 |
22,449 |
2.81 |
- |
|
| Ferrara Robert L |
Director |
– • – |
2025-05-20 |
4 |
B |
$1.82 |
$4,550 |
D/D |
2,500 |
13,166 |
2.31 |
- |
|
| Freeman Jonathan E |
Director |
– • – |
2024-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
1,000 |
|
- |
|
| Infarinato Robert M. |
VP, CFO |
• – – |
2024-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
11,000 |
|
- |
|
| Bitterman Robert J |
Chairman, Pres & CEO |
• • – |
2024-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
15,500 |
17,832 |
|
- |
|
| Lockshin Curtis |
Director |
– • – |
2024-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
2,000 |
|
- |
|
| Bradford Patricia A |
Director |
– • – |
2024-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
8,000 |
|
- |
|
| Ferrara Robert L |
Director |
– • – |
2024-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Infarinato Robert M. |
VP, Chief Financial Officer |
• – – |
2024-08-13 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
8,000 |
|
- |
|
| Bitterman Robert J |
President & CEO |
• • – |
2024-06-07 |
4 |
B |
$0.74 |
$740 |
D/D |
1,000 |
20,990 |
2.73 |
- |
|
| Bitterman Robert J |
President & CEO |
• • – |
2024-06-06 |
4 |
B |
$0.75 |
$750 |
D/D |
1,000 |
19,990 |
2.73 |
- |
|
134 Records found
|
|
Page 1 of 6 |
|
|
